Drug design and new agents at ENA 2026

Nov 18–20, 2026 Barcelona, Spain ~1.5k attendees Website

45 organizations at ENA 2026 present work in drug design and delivery, degraders and new agents: 20 universities and institutes, 18 drug developers, 5 cancer centres and hospitals and 2 CROs and suppliers. Between them they bring 95 presentations to the program. Most represented: MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center and University of Michigan. As of Oct 13, 2026.

All 254 organizations at ENA 2026 →

Showing 1–7 of 45 organizations

Organization	ENA 2026 Attendance
MD Anderson Cancer Center Houston, Texas
mdanderson.org Cancer centres & hospitals University of Texas cancer centre for patient care, research and early-phase clinical trials.	Session Wed Nov 18 4:15–5:45pm Workshop 2: Radiopharmaceuticals ADCs & radioligands Talk Wed Nov 18 4:55–5:15pm Part of Workshop 2: Radiopharmaceuticals Translating Radiopharmaceutical Innovation from Bench to Bedside ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Translational validation of uPARAP (MRC2) as an antibody–drug conjugate target in osteosarcoma patient-derived xenograft models ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Preliminary phase 1 results from AVENTINE-1, a phase 1/2 study of AVZO-1418, an EGFR-HER3 bispecific antibody-drug conjugate (BsADC) for the treatment of patients with locally advanced or metastatic solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Antibody-drug conjugates Population pharmacokinetics (popPK) and exposure-response analyses of sacituzumab tirumotecan (sac-TMT) antibody-drug conjugate (ADC) in participants (pts) with advanced solid tumors ADCs & radioligands Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers TROP2 Predicts Response to TUSC2 Gene Therapy (Quaratusugene Ozeplasmid) and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment Targeted agents Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Translational Studies Targeting the PI4K2A lysosomal pathway is a promising approach for lung cancer therapy Biomarkers Talk Thu Nov 19 10–10:10am Part of Plenary Session 3: Proffered Papers Phase 1 trial and translational study of the glutaminase-1 (GLS1) inhibitor IACS-6274 in combination with bevacizumab and paclitaxel in patients with advanced ovarian cancer Early clinical · Targeted agents Session Thu Nov 19 2–2:30pm Posters in the Spotlight, session 1 Session Thu Nov 19 3–4:30pm Workshop 3: End-to-End Early Clinical Development Through AI AI · Early clinical Session Thu Nov 19 3–4:30pm Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Genomics Talk Thu Nov 19 3:20–3:40pm Part of Workshop 3: End-to-End Early Clinical Development Through AI Radiology - Digital twins and multiomics AI · Early clinical Talk Thu Nov 19 3:40–4pm Part of Workshop 4: Next-Generation Precision Oncology: Progress, Pitfalls and Promise Rewiring the Cell Cycle: Early Clinical Insights from Next-Generation Cyclin and CDK Targeting Genomics Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Delivery A Bayesian pharmacokinetics-integrated Phase I–II design to optimize dose-schedule regimes Drug design Talk Fri Nov 20 3–3:10pm Part of Plenary Session 7: Proffered papers Interim results from the ﬁrst-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) Early clinical · Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: Combination Therapies Discovery of novel combination strategies to target SWI/SNF mutant lung cancers Targeted agents
Memorial Sloan Kettering Cancer Center New York, NY
mskcc.org Cancer centres & hospitals Cancer treatment and research centre with clinical, laboratory and computational research programmes.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Drug Resistance and Modifiers A super glue to trap wild-type and mutant variants of the ARAF:MEK1 complex Targeted agents Talk Thu Nov 19 8–8:25am Part of Plenary Session 2: RAS pathway: "Targeting RAS - What's Next?" Brief clinical overview, mechanistic insights into resistance and RBD mutation studies Targeted agents Talk Thu Nov 19 4–4:20pm Part of Workshop 3: End-to-End Early Clinical Development Through AI Therapeutic selection – drug design and protein folding AI · Early clinical Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New agents for paediatric oncology Safety and efficacy of autologous tumor infiltrating lymphocyte therapy in pediatric and adolescent patients with immune checkpoint inhibitor-refractory metastatic melanoma: Results from a phase I clinical trial Targeted agents Talk Fri Nov 20 12:15–12:25pm Part of Plenary Session 6: Proffered papers ARV-806, a PROTAC KRAS G12D Degrader, in Patients With KRAS G12D–Mutated Advanced Solid Tumors: Preliminary Phase 1 Results Drug design · Early clinical
University of Michigan Ann Arbor, MI
umich.edu Universities & institutes Public research university in Ann Arbor whose Rogel Cancer Center runs cancer research and clinical care.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Design Discovery of JZY3032, a First-in-Class DALTAC Rewiring AR-p300 Demonstrate Lineage-Selective Anti-tumor Efficacy in Advance Prostate Cancer Models Drug design Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents CRBN-Based Pan-KRAS PROTAC Degraders with Sub-Nanomolar Potency and Broad In Vivo Efficacy Across Clinically Relevant KRAS Mutant Tumors Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Discovery of clinical candidate SD-1240, a potent and selective STAT3 PROTAC degrader Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Discovery of RPT04402, a first-in-class molecular glue activator with potent and selective anti-tumor activity in PPP2R1A mutant cancers Drug design
Astellas Tokyo, Japan
astellas.com Large pharma Pharmaceutical company with marketed cancer drugs and a pipeline including KRAS inhibitors and degraders.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents ASP2453, a novel KRAS G12C inhibitor, shows potent anti-tumor activity in various KRAS G12C-mutated preclinical models including genetically engineered mouse model Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Characterization of KRAS-G12D ubiquitination and degradation by setidegrasib (ASP3082) and its combination potential in preclinical models Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs ASP5834, a novel pan-KRAS degrader, shows potent anti-tumor activity in KRAS mutant cancer models Drug design
Institute of Oncology Research (IOR) Bellinzona, Switzerland
ior.usi.ch Universities & institutes Cancer research institute affiliated with Università della Svizzera italiana, with programmes including lymphoma and prostate cancer.	Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Drug Screening High-throughput synergy screening of blood-brain-barrier penetrant compounds identifies druggable targets that potentiate BTK inhibition in CNS lymphomas Preclinical models Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents Transcriptional and epigenetic inducers of proximity as antitumor agents in marginal zone lymphomas Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents First characterization of the synthetic peptide CIGB-552 in B-cell lymphomas demonstrates antitumor activity in drug-resistant models and enhancement of BTK-targeted therapies Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: Molecular Targeted Agents The CBP/EP300 inhibitor TT125-802 shows antitumor activity in marginal zone lymphoma models and can improve the effects of BTK inhibitors Targeted agents Poster Thu Nov 19 9:30–10am 1–3pm 4:30–5pm Part of Poster session: New therapies in immuno oncology FF01, a novel heavy chain antibody targeting the human endogenous retrovirus envelope, displays anti-lymphoma activity Immuno-oncology Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs BTK and BCL2 targeting with orelabrutinib (ICP-022) and mesutoclax (ICP-248): single-agent and combination activity in marginal zone lymphoma, including drug-resistant derivatives Drug design Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Natural extracts show anti-proliferative activity in lymphoma cells with resistance to targeted agents Drug design
Chia Tai Tianqing Lianyungang, China
cttq.com Large pharma Pharmaceutical company, part of Sino Biopharmaceutical, developing targeted cancer drugs including degraders and molecular glues.	Poster Wed Nov 18 12–1:30pm 3:50–4:15pm 5:45–7pm Part of Poster session: Epigenetic modulators (HDAC Bromodomain modulators, EZH2) TQB3306: a second-generation menin-MLL inhibitor overcoming acquired MEN1 resistance with superior efficacy in acute leukemia models Targeted agents Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Novel fourth-generation ALK inhibitor TQB5410 demonstrates potent activity against ALK-positive cancer Drug design Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs TQB3142, a clinical-stage BCL-XL PROTAC, demonstrates robust in vivo antitumor activity and a favorable pharmacokinetic profile as a potential best-in-class therapeutic Drug design Poster Fri Nov 20 10:45–11:15am 1:30–3pm Part of Poster session: New drugs Preclinical activity of TQB3125, an orally bioavailable pan-RAS(ON) molecular glue for KRAS-mutant pancreatic cancer Drug design
Novartis Basel, Switzerland
novartis.com Large pharma Global pharmaceutical company with oncology medicines including radioligand therapies and targeted agents.	Talk Wed Nov 18 5:15–5:35pm Part of Workshop 2: Radiopharmaceuticals Implementing Radioligand Therapy early trials in the Real World: Site selection, Implementation, and Supply-Chain Challenges ADCs & radioligands Session Fri Nov 20 9:30–10:45am Workshop 8: Proximity inducers beyond current PROTACs Drug design Talk Fri Nov 20 9:30–9:35am Part of Workshop 8: Proximity inducers beyond current PROTACs Setting the scene: The new world of proximity inducing therapeutics Drug design